Thank you, Mr. Chair.
Thank you to everyone for presenting today. There are a lot of familiar faces in the room today.
Mr. Sinclair, I would like to thank you for your comments. Unlike my colleague, something that I'm hearing continually is the concern for the cost of pharmaceutical drugs in Canada. Canadians overwhelmingly are suffering under the high cost of drugs. Twenty-five percent of Bill C-30 is patent changes. This will have an overarching cost impact on things like Canadians' retail purchasing power. It will be taken out of their hands, because they will have to pay higher costs for pharmaceuticals.
We've asked for an analysis from the lead negotiator, and we don't have one. The Liberals in previous Parliaments also pushed for a comprehensive analysis on the impacts to provinces and to Canadians for the loss.
Can you tell me if you know of any such analysis that exists at the government level, and then can you speak to the analysis that the CCPA has done on this issue?